ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Global Management Forum 2019

Casino operator says Japan can 'easily' double tourists

Melco's Ho and Red Planet Hotels' Hansing suggest boom won't end with Olympics

Melco Resorts and Entertainment Chairman and CEO Lawrence Ho is eyeing a large integrated resort project in Yokohama. (Photo by Karina Nooka)

TOKYO -- Japan can "easily" meet its target of doubling the number of foreign tourists, the head of Hong Kong-based casino operator Melco Resorts & Entertainment told a conference on Tuesday.

"A lot has changed in Japan for the better in terms of the accessibility for international visitors," Lawrence Ho, Melco's chairman and CEO, said during a speech at the Nikkei Global Management Forum in Tokyo. "60 million is a very easy figure to accomplish."

The annual two-day forum, which wrapped up Tuesday afternoon, focused on digital trends and survival strategies for companies in uncertain economic times. Ho spoke during a session on the hospitality and tourism industry, following appearances by high-profile guests including Grab co-founder Tan Hooi Ling, Barclays CEO Jes Staley and Takeda Pharmaceutical CEO Christophe Weber.

Japan attracted a record 31.1 million foreign tourists in 2018 -- nearly triple the figure five years earlier -- in the run-up to the 2020 Tokyo Olympics. It aims to double the number again, to 60 million, by 2030. To capture the windfall, Melco is eyeing a bid to build an integrated resort in Yokohama.

The surge in tourists has been a major boon for a broadly stagnant Japanese economy. On the other hand, the rapid development of hotels and commercial facilities has raised concerns about oversupply once the Olympics are over.

Timothy Hansing, CEO of Red Planet Hotels, a Thailand-based budget hotel chain, brushed off such worries. "The Olympics is not the peak of tourism," he said, adding that the "growth of demand [in Japan] is staggering."

The forum covered plenty of ground over the course of the day, including the importance of innovation and strategies for tackling global issues like climate change.

Hideki Kobori, president of Japanese chemical company Asahi Kasei, said corporations must "create an environment to nurture high-level expertise and specialists" to drive growth. The company's reputation received a boost recently when its honorary fellow, Akira Yoshino, won a Nobel Prize for chemistry.

Hans Van Bylen, CEO of German consumer goods and chemicals maker Henkel, said broad alliances are essential for confronting global problems like climate change and pollution. This can even involve teaming up with rivals, he said, citing a joint initiative to end plastic waste that Henkel "took together with one of our big competitors."

Earlier on Tuesday, speakers explored the wealth of opportunities in Asian markets as well as the potential risks of the U.S.-China trade war and other upheavals.

Grab's Tan Hooi Ling said the true economic potential of Southeast Asia is only just coming into view, seven years after the ride hailer was founded. The region's "digital economy," she said, "is going to triple by 2025."

Tan noted that Southeast Asia is a diverse region as well as a young one, with an average age of just 30 and more mobile phones than bank accounts. "Where others see chaos, we see opportunity," she said.

Detailing the company's diversification into other services like food deliveries and e-payments, she said, "We use technology to unlock the potential of Southeast Asia in ways that have not been done before." And she stressed that it is not doing it alone: Grab is backed by SoftBank Group and has formed strategic partnerships with Toyota Motor and Honda Motor.

Barclays' Staley, meanwhile, weighed in on how the U.S.-China trade conflict is creating challenges for companies in Europe.

Barclays CEO Jes Staley, right, speaks with Financial Times Editor-in-chief Lionel Barber. (Photo by Karina Nooka)

"You've got five big tech companies in the U.S., then you've got five major U.S. banks that dominate the global capital market," he said. "What does that mean in terms of geopolitical competition? Will the rest of the world, will the U.K., will Europe, be at one level forced to pick a side? That would be a pretty uncomfortable place for everybody to be in. That's a possibility."

Staley also warned of uncertainty stemming from central banks' rush to cut interest rates to ultralow levels. "The transmission mechanism of dropping interest rates to generate economic growth is running out of steam," he said.

"If the current monetary policy is going to be a contributor to sustained economic growth, it's got to be matched by more growth-oriented fiscal policy in Europe and the U.K."

Takeda's Weber also expressed concern about the trade war, even though Japan's largest drugmaker has yet to feel significant effects. "This is something we are closely looking at," Weber said. At Takeda, one factory supplies a given medicine worldwide. "If the world is starting to bifurcate, it will complicate our life a lot."

Still, despite the hazy global outlook, Weber is pressing ahead with a major international expansion drive. The company is preparing a flurry of product launches in China, he told the forum.

Takeda Pharmaceutical President and CEO Christophe Weber shares the company's big plans for China. (Photo by Arisa Moriyama)

"We are planning to launch more than 10 new medicines in the next three years in China," Weber revealed. "There is a huge evolution going on" in China's health care industry in terms of approvals for innovative medicines, he added.

Weber presided over one of the largest acquisitions ever in the pharmaceutical industry, when Takeda completed its roughly $60 billion purchase of Irish peer Shire earlier this year.

"We think speed matters a lot," Weber said, noting that "the pharmaceutical market is growing very fast in China, in emerging countries and in the United States." The faster a drugmaker can release unique products, the higher the profit margin will be, giving the company more resources to spend on further research and development -- a virtuous cycle.

That is crucial at a time when drugmakers face skyrocketing investments in research and development.

Weber said that Takeda will focus on fewer diseases and accelerate product launches through partnerships with various outside organizations, including technology companies and academia. "We don't mind products coming from our own research lab or externally. This is a new mindset of partnering," Weber said, adding that his company has forged 200 collaborative research arrangements in the last four years, in and outside Japan.

Find out more about the event here.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media